Kura Oncology Spins Out Caspian Therapeutics to Target Diabetes with Menin Inhibitors

  • Kura Oncology spins out Caspian Therapeutics to focus on menin-directed therapies for diabetes and cardiometabolic diseases.
  • Caspian's lead compound, KO-7246, is in IND-enabling development for diabetes, targeting functional β-cell capacity and insulin production.
  • Investor webcast scheduled for October 13, 2026, to discuss Caspian's launch and KO-7246 preclinical data presented at the 62nd EASD Annual Meeting.
  • Kura Oncology retains focus on oncology with its FDA-approved menin inhibitor, KOMZIFTI (ziftomenib).

Kura Oncology's spin-out of Caspian Therapeutics reflects a strategic pivot toward leveraging its menin inhibitor expertise beyond oncology. This move aligns with the broader industry trend of repurposing cancer therapies for metabolic diseases, capitalizing on existing research to reduce development timelines and costs. The success of this strategy will depend on Caspian's ability to translate preclinical promise into clinical efficacy, while Kura maintains its leadership in oncology with KOMZIFTI.

Clinical Progress
The pace at which KO-7246 advances through Phase 1 trials and demonstrates efficacy in restoring β-cell function in diabetes patients.
Market Differentiation
Whether Caspian can carve out a distinct niche in the competitive cardiometabolic disease space with its menin inhibitor platform.
Strategic Focus
How Kura Oncology balances its oncology pipeline with the new focus on cardiometabolic diseases through Caspian Therapeutics.